<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766736</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0258</org_study_id>
    <nct_id>NCT04766736</nct_id>
  </id_info>
  <brief_title>Netrin-1 &amp; Hepatocellular Carcinoma HCC</brief_title>
  <acronym>HCC-Net</acronym>
  <official_title>Netrin-1 in Hepatocellular Carcinoma: Pathology, Preclinical Targeting, and Definition of Eligibility Criteria for Phase 1 Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer&#xD;
      types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that&#xD;
      netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize&#xD;
      netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing&#xD;
      netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to&#xD;
      benefit from this targeting approach in the clinic.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Netrin-1 expression patterns in HCC samples</measure>
    <time_frame>Outcome measure is to be performed after surgery of the tumors (at least 1 year later). It has no impact on the patient's care.</time_frame>
    <description>Netrin-1 expression levels will be quantified by immunoblotting with ad hoc internal standards. Positivity threshold by IHC will be evaluated using ad hoc positive and negative control tissues. The densitometry approach will be used.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>HCC</condition>
  <arm_group>
    <arm_group_label>Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)</arm_group_label>
    <description>The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)</arm_group_label>
    <description>The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quantification of netrin-1 signals by antibody-based approaches</intervention_name>
    <description>Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.</description>
    <arm_group_label>Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)</arm_group_label>
    <arm_group_label>Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Both men and women, between 18 and 85 years of age, suffering from Hepatocellular&#xD;
        Carcinoma.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any patient suffering from HCC&#xD;
&#xD;
          -  age &gt;18&#xD;
&#xD;
          -  informed consent provided&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - absence of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabien ZOULIM, Pr</last_name>
    <phone>4 26 10 93 55</phone>
    <phone_ext>+33</phone_ext>
    <email>fabien.zoulim@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romain PARENT</last_name>
    <phone>4 72 68 19 70</phone>
    <phone_ext>+33</phone_ext>
    <email>romain.parent@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hepatogastroenterology service of the Croix-Rousse Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien ZOULIM, Pr</last_name>
      <phone>4 26 10 93 55</phone>
      <phone_ext>+33</phone_ext>
      <email>fabien.zoulim@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

